Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
NCT00501163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38
Last updated 2018-06-19
Summary
Participants will be asked to do the following:
1. A screening session in which you will take part in a diagnostic interview that will take about 2-3 hours to complete and will address your medical history. If you've recently participated in one of Dr. Haupt's or Dr. Newcomer's studies (HRPO #03-1281, 01-0134, or 04-0191) you may not have to complete this screening interview.
2. An ultrasound test of your heart and blood vessels where an ultrasound machine will use sound waves to create images that allow the main blood vessels in your neck to be examined. You will be lying down for the procedure, and a colorless gel will be applied to the side of your neck where the handheld probe (called a transducer) will be placed. The transducer will then be gently moved over each side of your neck. This procedure will take approximately 30 minutes.
3. A magnetic resonance image (MRI) study where the amount of fat in your liver will be measured. The MRI involves having your body painlessly scanned inside a tubular machine, while lying on a table for about 45 minutes.
4. Some routine blood tests to assess glucose (sugar) and lipid (fat) control and liver function, as well as an additional hepatitis screen if you have a history of hepatitis. You will go to the Intensive Research Unit (IRU) or Clinical Trials Unit (CTU) after an 8 to 10-hour overnight fast (except water). Approximately 42 ml (3 tablespoons) of blood will be obtained from you, and you will also have your height, weight, blood pressure, and waist and hip measurements taken. This will take approximately one hour.
5. A dual energy x-ray absorptiometry (DEXA) scan to measure your body fat and body muscle content. The DEXA scan involves lying on a table in a private room wearing a hospital gown for about 15 minutes while a machine silently measures the amount of fat in your body. The DEXA scan is part of the research study and gives the researcher a picture of how much fat is in your body.
Conditions
Sponsors & Collaborators
-
National Alliance for Research on Schizophrenia and Depression
collaborator OTHER -
Washington University School of Medicine
lead OTHER
Principal Investigators
-
Daniel W Haupt, MD · Washington University School of Medicine
Eligibility
- Min Age
- 10 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-08-31
- Primary Completion
- 2012-05-31
- Completion
- 2012-05-31
Countries
- United States
Study Locations
More Related Trials
-
Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome
NCT00018837 ·Status: COMPLETED ·Phase: NA
-
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II
NCT00377117 ·Status: COMPLETED
-
Coronary Artery Disease in Patients Suffering From Schizophrenia
NCT02885792 ·Status: UNKNOWN ·Phase: NA
-
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
NCT05245539 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
NCT01222793 ·Status: COMPLETED
-
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
NCT01215383 ·Status: UNKNOWN
-
Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia
NCT05174533 ·Status: UNKNOWN
-
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
NCT05509998 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Mental Health During the Whole Life Cycle of Community Patients with Schizophrenia
NCT05159349 ·Status: RECRUITING
-
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
NCT00825539 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
5HT3 Antagonism and Auditory Gating in Schizophrenia
NCT00018850 ·Status: COMPLETED ·Phase: NA
-
Brain Imaging in Early Psychosis
NCT03932188 ·Status: UNKNOWN
-
Psychiatric Disorders and Electrophysiological Markers
NCT02329119 ·Status: UNKNOWN ·Phase: NA
-
Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia
NCT00001323 ·Status: COMPLETED
-
Neuromodulation for Schizophrenia
NCT05580211 ·Status: RECRUITING ·Phase: NA
-
Promoting Cognitive Health in Schizophrenia
NCT05661448 ·Status: RECRUITING ·Phase: NA
-
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
NCT01163227 ·Status: COMPLETED ·Phase: PHASE2
-
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981 ·Status: COMPLETED
-
Neuronal Effects of Exercise in Schizophrenia
NCT02455193 ·Status: RECRUITING ·Phase: NA
-
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
NCT05919823 ·Status: COMPLETED ·Phase: PHASE3
-
An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia
NCT01634542 ·Status: COMPLETED
-
Reducing the Weight of Overweight Schizophrenia Patients
NCT00158366 ·Status: COMPLETED ·Phase: NA
-
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population
NCT00253240 ·Status: COMPLETED
-
Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry
NCT01611337 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
NCT05106309 ·Status: COMPLETED ·Phase: PHASE1